What question did this study set out to answer?

This research aims to explore novel combinations of therapies to overcome resistance to PD-(L)1 blockade in rare cancers.

June 6, 2026

Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers

Key Points

This research aims to explore novel combinations of therapies to overcome resistance to PD-(L)1 blockade in rare cancers.
Investigated GRWD5769 in combination with cemiplimab against PD-1 resistance.
Evaluated IOS-1002 with pembrolizumab for immunosuppressive receptor inhibition.
Updated findings from the DART (NCI/SWOG S1609) study on ipilimumab with nivolumab.
GRWD5769 combined with cemiplimab shows promise in PD-1 resistance mitigation.
IOS-1002 combined with pembrolizumab targets LILRB1/2 and KIR3DL1 effectively.
Ipilimumab plus nivolumab demonstrates potential benefits for gestational trophoblastic neoplasia.

Abstract

The ERAP1 inhibitor GRWD5769 combined with cemiplimab, a PD-1 inhibitor, has shown preliminary promise in overcoming resistance to PD-(L)1 blockade by targeting antigen processing. Another resistance-mitigating strategy is potentially IOS-1002, an antagonist of two immunosuppressive receptors, LILRB1/2 and KIR3DL1, combined with anti-PD-1 pembrolizumab. As well, an update on the recently published DART (NCI/SWOG S1609) study indicates that the classic combination of ipilimumab with nivolumab may benefit even more rare cancers, including gestational trophoblastic neoplasia.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Cancer Discovery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study